Focal Segmental Glomerulosclerosis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2028

 

Focal Segmental Glomerulosclerosis Market


Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease that affects the kidney's filtering system (glomeruli) and causes severe scarring and end-stage renal disease. According to an article published in the Clinical Journal of the American Society of Nephrology in 2017, FSGS incidence rates are often higher in men, an estimated 1.5-fold higher than in women. Edema, proteinuria, weight gain, increased cholesterol, and proteins in the blood are symptoms of FSGS.

There is currently no approved treatment for the Focal Segmental Glomerulosclerosis Market. As a result, limited treatment options and government funding for rare disease research are expected to propel the Focal Segmental Glomerulosclerosis Market forward.

Scar tissue in the kidney's filtering unit is known as focal segmental glomerulosclerosis. The glomerulus is the name for this structure. The glomeruli function as filters, assisting the body in eliminating harmful substances. Each kidney contains thousands of glomeruli. "Focal" means that some of the glomeruli scar.

Rising numbers, as well as significant untapped opportunities in the market due to a limited number of pipeline products, are helping to drive it. Non-governmental organizations' ongoing efforts to raise awareness about rare diseases, as well as increase funding for rare disease research, are proving beneficial to the market for focal segmental glomerulosclerosis.

The Focal Segmental Glomerulosclerosis Market can be divided into two types based on the disease type: primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis. Primary focal segmental glomerulosclerosis accounted for 79.8% of the market in 2016. Primary focal segmental glomerulosclerosis, also known as primary idiopathic/genetic focal segmental glomerulosclerosis, is a type of focal segmental glomerulosclerosis disease that has no known or obvious cause. Growing awareness of the disease and its management is at the forefront of driving the segment growth.

Key Players

GlaxoSmithKline plc., Novartis AG, Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., Pfizer, Inc., AstraZeneca plc., Sanofi S.A, and Teva Pharmaceutical Industries Ltd. are the key players in the focal segmental glomerulosclerosis (FSGS) market.

Comments